NCT06051851View on ClinicalTrials.gov

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

July 1, 2025

Study Completion Date

July 1, 2026

Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
DRUG

Penpulimab

"Penpulimab 200mg IV D1~1 cycle every 21 days"

DRUG

Anlotinib

"Anlotinib 12mg/10mg P.O. QD D1-14 (12mg for body surface area ≥1.6m2, 10mg for body surface area ≤1.6m2)~1 cycle every 21 days"

DRUG

Nab paclitaxel

"Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days"

DRUG

Gemcitabine

"Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days"

Trial Locations (1)

210008

RECRUITING

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Nanjing

All Listed Sponsors
lead

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

OTHER